Catalyst (CPRX) Loses 12.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Group 1 - Catalyst Pharmaceutical (CPRX) has experienced significant selling pressure, resulting in a 12.2% decline over the past four weeks, but analysts expect better earnings than previously predicted [1] - The Relative Strength Index (RSI) for CPRX is currently at 25.06, indicating that the stock is in oversold territory, which may suggest a potential reversal in trend [5][7] - Over the last 30 days, the consensus EPS estimate for CPRX has increased by 0.9%, indicating a positive trend in earnings estimate revisions that typically correlates with price appreciation [7][8] Group 2 - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8]